Medizone International, Inc. (OTCBB:  MZEI) is in the very advanced stage of developing AsepticSure™ technology which fights hospital acquired infections.  The sterilization of contaminated hospital spaces with a fully portable unit is now within reach without enormous expense, which will translate into greatly reduced suffering, thousands of lives saved and a dramatic cost benefit for the health care system globally.

Congress is focusing in this and studies are providing the ammunition.  A solution to Hospital Acquired Infections will be the next big break through in medicine.

MZEI announced that production of AsepticSure™ is imminent.  The news continues to point to the need for a solution and that is precisely what MZEI will provide. MZEI is in the perfect stage of development for investors. 

MUST Read Report:
Duke University Study Indicates Managing Hospital Acquired Infections is Crucial

A recent report from researchers at Duke University in North Carolina indicates that a single patient infected with the increasingly common “superbug” known as MRSA can cost a hospital $60,000.    After a study conducted in seven hospitals and health facilities the Duke report indicates that taking action to fight infections can save money.  

The report noted, “Surgical site infections due to MRSA led to charges in excess of $19 million for the group [of seven] study hospitals.”

The study, published in the Public Library of Science journal PLoS ONE, addresses methicillin-resistant Staphylococcus aureus or MRSA infections associated with surgery and notes:

• MRSA after surgery raises death risk seven fold
• Patients were seven times more likely to die in 90 days post surgery
• Hospitals spend thousands on readmission after surgery
• A  35-fold increased risk of hospital readmission
• More than three weeks of additional hospitalization
• More than $60,000 of additional charges compared to uninfected controls

“Our estimates of the financial burden of surgical site infections due to MRSA are unique,” Deverick Anderson of Duke University Medical Center and colleagues wrote.

For their study, Anderson’s team looked at records from more than 140,000 surgical procedures done between 1998 and 2003.

They found and compared the cases of 150 patients with MRSA infections from the surgery, 128 with Staphylococcus aureus infections that were not resistant to the strong antibiotic methicillin and 231 similar patients who did not get infections.

The study, available at http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.po ne.0008305, suggests it is worthwhile for hospitals to clean up, do more infection control and even hire a staffer to take on the issue.

Recently,  U.S. researchers reported that MRSA cases have risen by 90 percent since 1999 and kill 20,000 people a year.

Contact information:
Medizone International, Inc. (OTCBB: MZEI)
(See Medizone International Video)
http://www.medizoneint.com

Telephone:  415-868-0300
Fax:  415-868-2344
Address:
Post Office Box 742
Stinson Beach, CA 94970

Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.